Ten years of very infrequent zoledronate therapy in older women: an open-label extension of a randomized trial.

CONCLUSIONS: These results suggest that zoledronate 5mg administered at a 5.5-year interval prevents bone loss over almost 11 years. Clinical trials to investigate whether very infrequent treatment with zoledronate reduces fracture risk are justified. PMID: 32016386 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32016386?dopt=Abstract

Source: The Journal of Clinical Endocrinology and Metabolism - February 3, 2020 Category: Endocrinology Authors: Grey A, Horne A, Gamble G, Mihov B, Reid IR, Bolland M Tags: J Clin Endocrinol Metab Source Type: research